Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series
Clinical and Experimental Medicine · 2025
DOI: 10.1007/s10238-024-01551-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Iman Adel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncologic Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Glypicans, Carcinoma, Squamous Cell, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.
Abstract (Originalsprache)
Lung cancer is one of the major causes of cancer morbidity and mortality. Subtyping of non-small cell lung cancer is necessary owing to different treatment options. This study is to evaluate the value of immunohistochemical expression of glypican-1 in the diagnosis of lung squamous cell carcinoma (SCC). This retrospective study included a total of 68 cases, of which 36 were diagnosed as SCC and 32 as adenocarcinoma (ADC). Furthermore, glypican-1 expression was compared with the expressions of p63, thyroid transcription factor-1 (TTF-1), and napsin A. All cases of SCC except one showed positive immunostaining to glypican-1; 35/36 (97.2%) cases, and predominantly scored 3 + . While only 5 cases of ADC showed positive immunostaining to glypican-1, having a score of 1 + or 2 + . The difference between glypican-1 expression of the two tumor types was highly significant ( p value < 0.001). The sensitivity, specificity, and overall accuracy of glypican-1 expression for differentiating lung SCC from ADC were 97.2%, 84.4%, and 91.2%, respectively. The sensitivity of glypican-1 is more than p63 in the diagnosis of lung SCC. Glypican-1 can be added as a new diagnostic marker to help in the accurate discrimination between poorly differentiated lung SCC and solid predominant adenocarcinoma cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncologic Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. fatma.samy@med.asu.edu.eg.
Förderung
- Ain Shams University
Zitieren
APA
Adel, I., Mahmoud, H. A., Khater, A. I., & Hafez, F. S. (2025). Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01551-5
Vancouver
Adel I, Mahmoud HA, Khater AI, Hafez FS. Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-024-01551-5
BibTeX
@article{Adel2025,
author = {Adel, Iman and Mahmoud, Heba A and Khater, Amira Ismail and Hafez, Fatma S},
title = {Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series},
journal = {Clinical and Experimental Medicine},
year = {2025},
doi = {10.1007/s10238-024-01551-5}
}
EUVIMED